Introduction
Multiple myeloma (MM) remains an incurable plasma cell malignancy that kills more than 15 000 people in the United States each year. The disease is disseminated throughout the bone marrow (BM) either as diffuse infiltrates of myeloma cells or as solid tumor nodules. Osteolytic bone lesions owing to increased osteoclast activity and elevations in paraprotein levels are characteristic of MM. Chemotherapy using corticosteroids, alkylating agents, proteosome inhibitors and thalidomide analogs prolongs survival but is not curative. 1 Thus, innovative MM targeted therapeutics are urgently needed.
Oncolytic viruses are attractive experimental therapeutics as they can potentially replicate and spread within tumors to directly induce tumor destruction or potentiate an antitumor immune response. 2 These viruses can be modified through genetic engineering to be tumor selective, be more potent through addition of therapeutic transgenes or tailored for non-invasive monitoring. 3 However, efficient delivery of viruses/ vectors to tumor sites remains a challenge. Accuracy and efficiency of delivery can potentially be achieved by retargeting vector tropism exclusively to tumor cells or tumor neovessels, thereby increasing vector selectivity and decreasing uptake by non-target tissues. We have been developing the attenuated strain of measles virus (MV) as an oncolytic agent for cancer therapy and retargeting virus tropism. 4, 5 The virus uses its envelope glycoprotein, hemagglutinin (H), to attach to one of two cellular receptors, CD46 or SLAM (signaling lymphocyte activation molecule) and the fusion (F) glycoprotein to mediate viral-cell membrane fusion. Subsequent expression of MV-H and MV-F proteins on surfaces of infected tumor cells leads to extensive intercellular fusion (syncytia formation) and cell death. To enable noninvasive monitoring of the pharmacokinetics of virotherapy in patients, oncolytic MV has been modified to express a soluble marker peptide, human carcinoembryonic antigen (CEA), or the human sodium iodide thyroidal symporter, which concentrates radioiodine in the infected tumor sites. 6, 7 These viruses have potent antitumor activities in animal models and are being evaluated in phase I trials for patients with recurrent ovarian cancer, glioblastoma and multiple myeloma. [8] [9] [10] However, the presence of pre-existing anti-measles antibodies in vaccinated individuals can pose a major obstacle to systemic measles virotherapy. Indeed, the problem of neutralizing anti-viral Abs is relevant to all virus-based therapies as repeat dosing will likely be required to achieve significant therapeutic gains. To bypass circulating antiviral antibodies, we have chosen to first test MV in patients with ovarian cancer and glioma, as the diseases are amenable to intraperitoneal or intratumoral injection of the virus. On the other hand, patients with MM are severely immunocompromised, have low/non-existent levels of anti-measles antibodies and systemic therapy is thus more likely to be therapeutically effective in these patients than in others. 11 Besides choice of delivery route, other strategies to evade or overcome the inhibitory effects of pre-existing antiviral antibodies can include surface modifications to mask the coat protein of viruses (eg polymer, polyethylene glycol) and use of cell carriers. [12] [13] [14] [15] Cells have served as 'Trojan horses' to deliver viruses, as virus production 'factories' nested in tumors, and to potentially protect viruses from neutralizing antibodies, although no studies have yet evaluated antitumor efficacy using cell carriers in the presence of pre-existing antiviral antibodies in vivo.
14, [16] [17] [18] [19] [20] [21] [22] [23] In this study, we explored the potential of using activated T cells as carriers for delivery of oncolytic MV to tumor sites. This approach should be highly feasible as natural measles virus infection is cell-associated, predominantly through lymphocytes and monocytes, and cell-free viremia has been undetectable. 24 In addition, expression of measles H and F fusogenic proteins on the infected cell carriers might facilitate transfer of the virus infection to tumor cells via heterologous cell fusion. Candidates for cell carriers include T cells, monocytes, tumor cells and mesenchymal stem cells. Out of these cell types, there is extensive human experience with the use of cytokine-activated T cells for adoptive transfer in immunotherapy. A typical protocol involves harvest of peripheral blood lymphocytes from the patient, CD3 isolation of the cells and expansion of the cells using various cytokine cocktail regimens. 25 While in culture, in vitro modifications to T cells have included transduction of cells to express tumor specific antigens or chimeric T cell receptors to facilitate tumor-specific cytolytic killing and induction of a tumor specific immune response. 26 In contrast to the immunotherapy strategy, we seek to use MV-loaded T cells as carriers to protect and deliver oncolytic measles virus to mice with multiple myeloma disease in the presence of antiviral antibodies (Abs) and achieve a favorable therapeutic outcome.
Results

Susceptibility of T cells to MV infection
Freshly isolated peripheral blood lymphocytes (PBLs) from 5 healthy donors were used immediately or activated by culture in media containing recombinant human interleukin-2 (IL-2) and phytohemagglutinin (PHA) for 1 to 2 weeks before use. We have previously shown that, in contrast to tumor cells, MV cytopathic effects in normal cells such as PBLs were significantly reduced with minimal (if any) intercellular fusion in MV-infected PBLs. 8 Efficiency of MV-green fluorescent protein (GFP) infection of freshly isolated PBLs, as quantitated by flow cytometry analysis of GFP-positive infected cells, ranged from 10 to 20% at multiplicity of infection (MOI) of 1.0 (Figure 1a) . Identity of the GFPpositive cells was determined by dual-color fluroscence activated cell sorter (FACS) using phycoerythrin (PE)-conjugated anti-CD3, anti-CD19 or anti-CD14 Abs. As shown in Table 1 , CD3+ T cells were the predominant cell type infected by MV-GFP compared to CD19+ B cells or CD14+ monocytes. To increase the numbers of cells available for in vivo experiments and to potentially enhance cell susceptibility to MV infection, we activated the PBLs in IL-2 and PHA for 1-2 weeks (Figure 1b) . Expansion of PBLs using this cocktail regimen resulted in predominantly T cells (Table 1) . Susceptibility of T cells maintained in IL-2/PHA medium for 1 or 2 weeks to MV infection was comparable and higher than freshly isolated cells ( Figure 1a ). As expected, efficiency of virus infection in the cells was increased by increasing the MOI, going up from 18% at MOI 0.5 to 50-60% at an MOI 4.0 (Figure 1b) . All subsequent in vitro and in vivo experiments were performed at MOI of 1.0 using T cells from donor 1, which had been activated with IL-2/PHA for 1-2 weeks.
Transfer of MV infection from T cells to tumor cells
Transfer of MV from infected cell carriers to target cells can occur via release of progeny virus or heterologous fusion with the H/F-expressing infected cell carrier. The amount of virus output from infected T cells was determined by TCID 50 titrations (50% tissue culture infectious dose) on Vero cells and found to be below the limits of detection. As reported previously 8 there was also minimal intercellular fusion between uninfected and infected T cells (data not shown). In contrast, mixing of MV-GFP-infected T cells with red DiI-labeled ARH-77 myeloma cells resulted in efficient transfer of MV infection, likely via heterofusion of the two cell types (Figure 2a-c) . This resulted in ARH-77 syncytia that were T cells as carriers for systemic measles HT Ong et al Figure  2d , the CEA levels increased with time in Vero-T-cell co-cultures. Thus, MV-CEA-infected T cells were able to transfer MV infection to Vero cells over 2 weeks, with the peak period being between 1 and 7 days post-infection. In contrast, cell-free viruses suspended in culture media were inactivated after 24 h incubation at 371C.
Virus-infected cells are protected from neutralizing anti-measles Ab
Sera from healthy volunteers served as a source of antimeasles Abs and titers were determined using an enzyme immunoassay (EIA, Diamedix Corporation, Miami, FL, USA) routinely performed by the Mayo Clinical Serology Laboratory to evaluate the immune status of subjects. A titer of 420 EU/ml is classified as positive for measles Abs. Measles immune serum from donor 1 with a high anti-MV titer of 200 EU/ml was used in all subsequent assays. Corresponding plaque reduction virus neutralization (250 plaque-forming unit MV) titer of the serum was 1:256. 27 
MV-GFP virus or pre-infected T cells (18 h postinfection)
were incubated with serum from donor 1 for 30 min at 371C. The cells were then washed once with PBS and overlaid on Vero cells. As expected, there was a corresponding increase in virus infection with increasing dilution of the measles immune serum (Figure 2e ). In contrast to cell-free virus, virus-infected cells were protected from the inhibitory effects of neutralizing antibodies and were able to transfer MV to the target cells post treatment with MV Abs. It is also important to note that compared to pre-infected T cell carriers, cellfree viruses were more efficient at infecting the target cells in the absence or very low titers of anti-MV Abs.
Multimodality imaging of delivery of MV-Luc by T cells to subcutaneous or disseminated myeloma xenografts
Two models of human MM, ARH-77 and KAS 6/1, were used to determine if MV-infected T cells could transfer the virus to subcutaneous ARH-77 or systemic KAS 6/1 myeloma disease disseminated in the BM of mice. In the first model, female 5-6 weeks old severe-combined immunodeficiency (SCID) mice bearing 0.5-1.0 cm subcutaneous ARH-77 tumors were given one intravenous tail vein injection of 1 Â 10 6 TCID 50 MV or 1 Â 10 6 preinfected T cells. The dose of virus used is therapeutically active in this model. 8 The T cells had been incubated overnight with virus (MOI 1.0) and washed three times in cold phosphate-buffered saline (PBS) before infusion into the mice. Percentage of infected cells was typically in the range of 30-40%.
Serial gamma camera imaging using Indium111-oxine labeling indicated that the majority of MV-GFP-infected T cells initially arrested in the lungs and later disseminated in the mice, localizing predominantly in the liver (Figure 3a and b) . Mice were killed 6 h after cell infusion and the amount of radioactivity was measured in the major organs. As shown in Figure 3b , 40% of T cells were found in the liver, 12% in lungs, 2% in the spleen and 1.5% in the tumor. Based on the calculation that 1.5 Â 10 6 cells were given initially to mice, it is estimated that there were 3.8 Â 10 4 virus-infected T cells per gram of tumor tissue. These T cells have not been modified for tumortargeting and their localization in these tumors is likely owing to passive accumulation.
Uninfected or MV-GFP-infected T cells were labeled with DiI and infused intravenously into tumor-bearing mice. Fluorescence microscopy of freshly harvested whole tissues confirmed the presence of red DiI-labeled T cells in the organs examined; liver, lungs, spleen (data not shown) and tumor (Figure 3c-i) . Single small red cells were seen as well as larger aggregates, likely as a result of fusion between the tumor cells and the red MV-GFP-infected T cells (Figure 3e and f). In contrast, no GFP-positive cells or 'red' syncytia were observed in tumors of mice that received uninfected red T cells (Figure 3c and d) . Higher resolution analysis of tumor sections using confocal microscopy confirmed the presence of GFP-positive 'red' syncytia, likely owing to fusion of Dil-labeled MV-GFP-infected T cells with ARH-77 tumor cells (Figure 3g-i) .
Delivery of measles virus encoding firefly luciferase (MV-Luc) by cell carriers and subsequent intratumoral viral spread was monitored intensively using bioluminescent imaging in a mouse bearing a subcutaneous ARH-77 xenograft and given one intravenous (i.v.) dose of MV-Luc-infected T cells (1 Â 10 6 ). As shown in Figure 4 , there was a rapid increase in luciferase activity which peaked at day 7, declined from day 9 to 18, suggesting either tumor regression and/or decline of the virus infection. Subsequent to the decline, we detected an increase in luciferase activity from day 20 to 35, likely owing to re-growth of the tumor and 'rekindling' of the virus infection. It is also interesting to note that the signal is now shifted to the left of the mouse, suggesting tumor re-growth on that side and the mouse was euthanized thereafter owing to tumor burden (Figure 4a) .
The potential of preinfected T cells to deliver MV-Luc to disseminated myeloma disease was also evaluated in a systemic human myeloma model. After i.v. administration, KAS 6/1 cells seed to the BM and proliferate as tumor nodules, eventually replacing the marrow and causing hind limb paralysis of the mice. In advanced disease, the tumors 'erupt' from the marrow and form nodules in the interscapular region, paraspinal muscles and liver. To enable monitoring of tumor burden in this systemic model, we transduced the KAS 6/1 cells with a lentiviral vector to express the soluble b-chain of human chorionicgonadotropin (bhCG) so that total tumor burden can be quantitated by measuring plasma levels of bhCG . 28 As shown in Figure 4b , both virus and virusinfected cells were able to traffick to and spread the virus infection within the tumors. When we plotted total tumor burden (plasma bhCG levels) against viral gene expression (luciferase activity), we found a very good correlation between total tumor burden in the mice and virus gene expression (r 2 ¼ 0.92) with a significant P-value of o0.0001. No significant luciferase signals were seen in measles naïve mice given MV-Luc at 30 min after virus infusion (Figure 5a ). In mice given MV-Luc-infected T cells, luciferase signals were detected in the lungs owing to arrest of T cells in the pulmonary circulation (Figure 5a) . However, at day 8, there were intense signals in tumors of both groups of animals. Intratumoral luciferase activity was quantitated (Figure 5b ) and found to be comparable in mice that received cell-free (n ¼ 5) or cellbound virus (n ¼ 5). In contrast to measles-naïve mice, no luciferase activity was detected in all 10 immunized mice at day 8 in immunized mice (Figure 5c ). Delivery of virus via preinfected T cells also did not result in transfer and spread of MV in these immunized mice (Figure 5c ). There were luciferase activity in the lungs of mice that received infected T cells at 30 min post-infusion but not at day 8. These data suggest that, in agreement with in vitro results in Figure 2 where infected cells were treated with anti-MV sera, neutralizing antibodies did not lead to the destruction of virus-infected cells in vivo but virus delivery using cell carriers and spread were inhibited by anti-MV antibody.
Degree of inhibition is dependent on Ab titers
To determine if virus delivery using cells is at all possible in the presence of anti-MV Ab and if the degree of inhibition is correlated with Ab dose, varying amounts (500, 200, 75 or 25 ml) of measles-immune serum from donor 1 (titer 200 EU/ml) were diluted with saline to a final volume of 0.5 ml and administered i.p. to tumorbearing mice. Control mice given the same amount of sera were euthanized, and sera from two to three mice were pooled and the titer of human anti-MV IgG was measured using a clinical (Diamedix) assay. The corresponding anti-MV Ab titers in mice that received 500, 200 and 75 ml of serum were 108 EU/ml, 64 EU/ml and 14 EU/ml, respectively. A titer of 420 EU/ml in humans is considered measles immune. The average titers of anti-MV Ab in healthy individuals and myeloma patients are 100759.17 EU/ml (n ¼ 10) and 36.58735.99 EU/ml (n ¼ 10), respectively. 11 As shown in Figure 5d and e, the amount of virus expression in the tumors was inversely correlated to the amount of anti-measles antibody administered. At the highest Ab concentration (500 ml or 108 EU/ml), virus and cells were neutralized or unable to fuse with the tumor cells. It is also apparent that virus-infected cell carriers and cell-free virus were able to overcome lower titers of anti-MV Ab to result in detectable luciferase expression in the tumors (Figure  5e ). At lower Ab dosing (75 ml or 14 EU/ml), viral gene expression was comparable using either method of delivery and the increases in luciferase activity were comparable to measles-naïve mice (Figure 5e ).
Discussion
Oncolytic measles viruses derived from the attenuated Edmonston vaccine lineage have promising antitumor activities and two recombinant MVs expressing transgenes to enable non-invasive monitoring of the pharma- 1.E+06
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T cells as carriers for systemic measles
HT Ong et al efficiently retargeted to tumor cells/neovessels through display of single-chain antibodies on the H attachment protein; (3) its excellent safety record in humans with millions of doses of vaccine routinely administered to preschool children throughout the world. Indeed, the success of these vaccination programs results in a high prevalence of pre-existing anti-viral antibodies in patients who pose a major challenge for use of MV in cancer therapy. Neutralizing anti-viral antibodies can inhibit virus delivery to the target site, preventing virus infection and subsequent viral spread. In addition, the role of cytotoxic T lymphocytes (CTLs) in virotherapy remains to be addressed; these CTLs could inhibit efficacy by removing virus-infected T cells or tumor cells but could also improve efficacy by harnessing the immune system to attack the infected tumor. To first address the issue of delivery in the presence of antibodies, we demonstrated here that systemically administered T cells can act as carriers to deliver MV to subcutaneous and disseminated human myeloma nodules in SCID mice. While previous studies have reported successful delivery of viruses to tumors using cell carriers and superior therapeutic efficacy compared to cell-free virus, no studies have reported on the utility of cell carriers for oncolytic viruses in the presence of pre-existing anti-viral antibodies in vivo.
14,16-23 Here, we compared free virus or virus-infected cells for systemic virotherapy in tumorbearing mice that were passively immunized with measles-immune serum and found that neither delivery strategy was able to overcome high titers of anti-viral antibodies. Indeed, both delivery and subsequent intratumoral viral spread were inhibited at high anti-viral titers (Peng, data not shown). When measles-immune serum were serially diluted and given to mice, both delivery methods transferred MV infection and intratumoral viral spread was detectable. Indeed, protection of humans from infection by wild-type MV is dependent on Ab titers. A titer of 4120 but o1052 from the plaque reduction neutralization assay protects against classic but not against mild clinical infections and those of 41052 indicate full protection against infection by wildtype MV. 29 It is thus apparent that virotherapy could be optimally therapeutic when combined with strategies that deplete or cause a transient decrease in pre-existing antiviral Abs. A possible Ab depletion strategy is plasmapheresis which can potentially deplete more than 90% of the immunoglobulins after 4-5 cycles. 30 This gives a 2-3 week time window for virotherapy to proceed before build-up of immunoglobulin levels.
As myeloma results from clonal expansion of malignant plasma cells, it is often associated with suppression of normal B-cell function, leading to profound hypogammaglobulinemia with very low titers of anti-measles antibodies. Indeed, efficacy of vaccination of myeloma patients against influenza, Streptococcus pneumoniae and Haemophilus influenza type B is poor, and only a small percentage of patients achieved protective antibodies owing to their impaired immune status. 31 Indeed, we previously determined that the average anti-MV Ab titers in myeloma patients (36.58735.99 EU/ml, n ¼ 10) were lower than in healthy individuals (100759.17 EU/ml, n ¼ 10). 11 This is an appealing feature that should favor measles virotherapy in this cohort of patients, especially as the current study demonstrates that cell-free virus can be delivered to and successfully spread in tumors at low titers of Ab. The kinetics of virus neutralization is then a mathematical equation between speed of neutralization, speed of virus trafficking to the tumors, numbers of viruses administered and numbers of neutralizing antibodies; these complex systemic interactions in space and time will require further in vivo studies.
Based on data from this study, we envisage that the ideal protocol for systemic measles virotherapy would combine antibody depletion strategies coupled with the use of virus-loaded cell carriers for delivery of MV infection to tumor sites. Using indium111 labeled cells, we estimated that 1-2% of the injected T cells reached the tumor nodules, a level comparable to that of systemically administered antibodies. 32 Localization of these T cells in tumors is likely owing to passive accumulation. However, expression of leukocyte function adhesion factor-1, which promotes adherence to endothelial cells, is increased in measles infected monocytes and lymphocytes and could aid in localization of virus-infected cell carriers to tumors. 33 As chemokines have been shown to enhance T-cell localization in the tumors, a potential strategy to enhance localization is via in vitro modification of T cells to express chemokine receptors. 34, 35 Owing to the logistics and mandatory validation of all clinical products and procedures, the value of elaborate in vitro modifications to the cell carriers needs to be carefully considered.
The type of cells to use as carriers will play an important role in determining the outcome of the therapy. Ideally, the virus should be able to amplify in the infected cell carrier and generate a large burst size at the tumor site. This increases the local concentration of viruses at the tumor site and may tip the neutralization equation in the favor of the virus. The use of cytokineinduced killer cells with vaccinia virus is an elegant pairing owing to the high tropism of vaccinia for T cells but also potentially high progeny output.
14 Natural measles viremia is cell-associated and cell-free virus is undetectable in the blood of infected individuals. 24 The wild-type virus uses SLAM receptor found on activated T cells, B cells and monocytes. 36 It is thought that in wildtype virus infection, infected immune cells carry the virus for dissemination to distant sites. In our study, the T cells were activated by high levels of PHA and IL-2 expansion and more studies are required to evaluate if T cells are the optimal cell carrier for MV. The attraction of T cells as carriers is the extensive human experience with adoptive T-cell transfer, chimeric T-cell receptor engineering to enhance antitumor immunity and wellestablished ex vivo expansion regimens that yield high numbers of T cells for systemic infusion. However, as reported previously normal cells such as PBLs are significantly less susceptible to MV infection compared to tumor cells, 8, 37 and would limit the efficiency of virus loading or amplification in the PBLs. Other possible cell carriers include the use of irradiated tumor cells, 18 which are highly susceptible to MV infection and support high levels of MV amplification, mesenchymal stem cells as they reportedly contribute to the stroma of tumors and thus would traffick to tumors. 23 These cell types should be examined as potential carriers for MV in combination with strategies (e.g. plasmapheresis) to transiently deplete pre-existing Abs to achieve optimal therapeutic outcome.
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Materials and methods
Cell culture and viruses
Vero African green monkey kidney cells were maintained in Dulbecco's modified Eagles's medium (DMEM) containing 5% fetal bovine serum (FBS). Human ARH-77 and KAS 6/1 cells were maintained in Roswell Park Memorial Institute (RPMI) medium containing 10% FBS. The KAS 6/1 media was supplemented with 1 ng/ml interleukin 6 (R&D Systems, Minneapolis, MN, USA). KAS 6/1 cells were also transduced with a HIV-1-based lentiviral vector expressing the b-chain of human chorionicgonadotropin (bhCG) to generate KAS-bhCG to allow non-invasive monitoring of tumor growth in vivo through analysis of levels of soluble peptide in the blood of the animals. 28 Blood from healthy volunteers were collected in heparinized tubes, layered on Ficoll-Paque Plus (Amersham Biosciences, Uppsala, Sweden) and centrifuged at 800 g for 30 min. The buffy coat was isolated and maintained in serum-free T-cell expansion medium (Sigma, St Louis, MO, USA). After monocyte depletion using plastic adherence, PBLs were expanded and activated in serum-free T-cell expansion medium containing 20-25 U/ml interleukin-2 (IL-2; R&D Systems) and 5 mg/ml PHA (Sigma). MV-GFP, MV-Luc, MV-CEA were propagated in Vero cells as described previously. 6 Briefly, cells were infected with viruses at an MOI of 0.02 for 2 h at 371C after which standard medium was added. When more than 80% of the cell monolayer was fused into syncytia, the cells were scraped into reduced serum medium, Opti-MEM (Gibco, Long Island, NY, USA), and subjected to two freeze-thaw cycles to release the cellassociated viruses. The viral supernatant was clarified by centrifugation and frozen at À801C until analysis. Virus titers were determined by TCID 50 titrations on Vero cells as described previously. 6 Anti-measles antibody titers Serum was collected using clot tubes from healthy volunteers and aliquoted. The aliquots of serum were frozen at À301C until use. Anti-measles antibody titers were determined by Mayo Central Clinical Laboratory using the Diamedix EIA assay. Positive titers ranged from 420 to 119.5 EU/ml. Plaque neutralization assays were performed as described previously. For plaque reduction virus neutralization assays, serial dilutions (4-fold) of serum were incubated with MV-GFP (250 TCID 50 ) for 1 h at 371C in 5% CO 2 and then plated in triplicate onto confluent Vero cells in 96-well plates. 27 After 1 h of incubation, inocula were removed and cells were cultured in 100 ml of DMEM containing 5% FBS. The numbers of plaques were counted at day 4 post infection. The dilution that prevents cytopathic effects in at least two out of three wells corresponds to the neutralizing titer.
Infection assays
Freshly isolated and IL-2/PHA-activated T cells were infected with MV-GFP at various MOI (0.5, 1, 2 and 4) for 2 h at 371C. At the end of the incubation, the virus was removed and the cells were maintained in IL-2-supplemented serum-free T-cell expansion medium in the presence of fusion inhibitory peptide to allow analysis of single infected GFP-positive cells by flow cytometry at 48 h post-infection. For analysis of PBL-subsets infected with MV-GFP, cells were collected 48 h post-infection and labeled with PE-conjugated monoclonal antibodies against CD3, CD14 and CD19 (BD Biosciences, Pharmingen, San Diego, CA, USA). Cells were incubated with the antibodies for 30 min at 41C. After staining, the cells were analyzed on a FACSCalibur flow cytometer (BD, San Jose, CA, USA) using the CellQuest software (BD).
In vivo experiments: imaging studies
All procedures involving animals were reviewed and approved by the Mayo Clinic Animal Use and Care Committee. The trafficking of T cells post-infusion into mice was monitored using a radioactive method or fluorescent method. T cells (2 Â 10 6 ) were incubated with 100 ml of Indium111 oxine (200 mCi) for 20 min at room temperature after which the cells were washed and resuspended in 100 ml PBS before i.v. injection via the tail vein into mice. Mice were anesthesized using ketamine (100 mg/kg) and xylazine (10 mg/kg) and imaged using a micro SPECT-CT imaging machine (X-SPECT, Gamma Medica, Northridge, CA, USA). MV-GFP-preinfected T cells were also incubated with Dil (Molecular Probes, Eugene, Oregon, USA) for 5 min at 371C, washed and infused i.v. into mice. Forty-eight hours later, mice were euthanized and organs harvested to determine the biodistribution and heterologous fusion of red fluorescent T cells with tumor xenografts using a fluorescence microscope. The transfer of MV-Luc infection from the infected T cells to tumor sites were monitored using luciferase imaging techniques. Mice were injected intraperitoneally with 3 mg/kg of D-luciferin (Xenogen Corporation, Alameda, CA, USA) and 10 min later, anesthesized via isoflurane inhalation. Mice were placed on the imaging platform and images were acquired between 15 and 30 min after luciferin injection. Images were analyzed using the Xenogen Living Systems 2.50 software.
Tumor models
Five-week-old female CB.17 ICR SCID mice (HarlanSprague-Dawley, Indianapolis, IN, USA) were irradiated (150 cGy) 1 day prior to tumor cell implantation. ARH-77 cells were implanted subcutaneously as back-pack or flank tumors. When tumors have reached more than 0.5 cm in diameter, the mice were given 1 Â 10 6 TCID 50 / 100 ml MV-Luc or 1 Â 10 6 T cells/100 ml PBS i.v. via the tail vein. For the disseminated myeloma model, KAS-bhCG cells (2 Â 10 6 cells/100ml) were injected i.v. through the tail vein into irradiated SCID mice. Mice received 2 doses of 1 Â 10 6 MV-Luc or 1 Â 10 6 T cells/100 ml PBS intravenously via the tail vein at 4 and 6 weeks after cell seeding. The T cells were infected with MV-Luc (MOI 1.0) the day before and left in culture overnight. Mice were imaged using the Xenogen Bioluminescent IVIS 200 Imaging System at regular intervals after virus or cell therapy. Total tumor burden in the systemic model was monitored by harvesting blood from the mice at regular intervals via the retro-orbital route and measuring bhCG levels by Mayo Central Clinical Laboratory, Bayer Healthcare, Terrytown, NY, USA (Bayer Centaur Immunoassay) in the plasma. For passive immunization studies, mice were given i.p. injection of saline or varying amounts of measles immune serum from donor 1 (anti-MV Ab titer 200 EU/ml or 1:256 plaque reduction virus neutralization titer) diluted in saline to a final volume of T cells as carriers for systemic measles HT Ong et al 500 ml. Three to five hours later, mice were given i.v. injections of virus or virus-infected cells.
